Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 4Terminated 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4CNS 1

Conditions

Melanoma 4

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × fotemustine × Dermatologic × Clear all
NCT01359956 2023-04-11

SICOG 0109

National Cancer Institute, Naples

Phase 3 Completed
269 enrolled 12 charts
Dermatologic

Melanoma

NCT01069627 2018-12-06

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Hoffmann-La Roche

Phase 2 Completed
20 enrolled 21 charts
Dermatologic

Melanoma

NCT01983124 2016-01-20

BeyPro1

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Phase 2 Completed
31 enrolled
Dermatologic

Melanoma

NCT01654692 2015-05-13

NIBIT-M1

Italian Network for Tumor Biotherapy

Phase 2 Completed
86 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡